I've been giving thought to whom would be the most logical partner right now,,,, as I look at their clinical trials,,,, I see that they using both Archexin and RX-3117 to improve or replace Gemcitabine,,, or Gemzar,,,, which, I believe is an Eli Lilly product,,,, so, I see them as a prime candidate
There is no Partnership until further positive findings in trial, Rexanh can even get enough patient to run their trial until the end of this year. ... get out now and buy back when patient recruit is complete.
Tim,,, ,according to Rexahn's corporate fact sheet,,,, they intend to complete the partnership for RX-3117 by mid 2014,,,, the word "complete" insinuates that the handshake has already taken place,,, I would expect that closing documents and any final negotiations are being completed,,, it would certainly be nice for Rexahn to announce that they are in negotiations and name the partner,,, Teva,,, Sanofi,,,, Lilly,,,, Novartis,,, whomever
they said mid year so it will be after. but the Excitement of the partnership will ensure that any negativity from the RS will rebound very quickly. and with more (most likely) positive trial updates to come afterwards will further propel the price of the stock. RS is for specific reason of attracting certain institutional investors....not forced to do so to meet nasdaq rules. there is a massive difference. i believe that when or if they do the RS, they will definitely do it in time to attract major institutions and then.....release news of partnership...they would do this for sure in order to make institutions money.